Introduction and Rationale
The sequelae of atherothrombosis, such as coronary heart disease (CHD), cerebrovascular disease and peripheral arterial disease are major causes of morbidity and mortality which ultimately causing premature death. Prevention of these cardiovascular diseases (CVD) requires modification of known risk factors for atherosclerosis such as blood pressure, cholesterol, high profile life style and smoking. 1 However, these risk factors only partially accounts for the risk of premature CVD and it is very likely that additional factors are of importance. 2 The interaction of oxidized LDL with arterial wall, endothelial cells, macrophages, vascular smooth muscle cells, platelets and circulating coagulation factors promotes atherosclerosis. 3, 4 Hypertriglyceridemia is an independent risk factor of CHD. A recent secondary prevention study of CHD with a statin suggested that it may be prudent to target fasting triglycerides (TG) to less than 150 mg/dl. Secondary prevention trials of CHD with drugs acting primarily on TG (fibrates) have shown that reducing TG and increasing high-density lipoprotein (HDL) cholesterol, without significantly affecting LDL slows down coronary artery luminal narrowing (Lopid Coronary Angiography Trial [LOCAT] , Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT] , Bezafibrate Infarction Prevention [BIP] ). Statins are also capable of significantly reducing high TG levels. 5 There are very few studies to investigate the LDL, TG lowering effect of statins in treatment of hypercholesterolemia in Bangladesh. This study is to evaluate atorvastatin in hypercholesterolemic risk patients with inadequate control to diet and exercise as well as the implication of NCEP ATP III guidelines. 6 Laboratory and experimental evidences suggest that statins can reduce the risk of cardiovascular disease events through modification of blood cholesterol:
Reductions in total and LDL cholesterol achieved with atorvastatin have been shown to translate into reductions in risk of cardiovascular morbidity and mortality in both primary and secondary prevention settings. 7 Significant clinical benefits have specifically been observed among patients with Type 2 diabetes and in those with acute coronary syndromes. 8, 9 In common with other members of the statin class, atorvastatin is well tolerated, and adverse events are generally mild and transient in nature. 10, 11 National Cholesterol Education Program (NCEP) Adult Treatment panel III (ATP III) guidelines and its implication: 6,12.13, 14 Since the publication of Adult Treatment Panel III (ATP III) of the US National Cholesterol Education Program, 5 major clinical trials of statin therapy with clinical end points have been published 15, 16, 17, 18, 19 . The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL) < 100 mg/ dl. They support the inclusion of patients with diabetes in the high-risk category and confirm the benefits of LDL lowering therapy in these patients. They further confirm that older persons benefit from therapeutic lowering of LDL.
When LDL-lowering drug therapy is employed in highrisk or moderately high-risk persons, it is advised that intensity of therapy be sufficient to achieve at least a 30% to 40% reduction in LDL levels 6 .
The need for atorvastatin evaluation in Bangladeshi patients:
Following the publication of US NCEP ATP III guidelines five major clinical trials of statin therapy were conducted in countries mostly located in North America, Western Europe and Latin America. The sub-group of patients of Asian origin was too small to be analysed separately. However, there were very few studies to investigate the LDL-lowering effect of statins in the treatment of hypercholesterolemia in Bangladesh.
This study was to evaluate the use of atorvastatin in the management of hypercholesterolemia of cardiovascular risk patients who were inadequately controlled to diet and exercise. Implication of US NCEP ATP III guidelines among the research clinicians was another intention of the study. Another objective was to measure the change of LDL and TG after 2 months of treatment and to assess patients' compliance to atorvastatin treatment.
Subjects and Methods

Patients:
A total 1685 patients aged 28 years or older who had evidence of hypercholesterolemia with or without Coronary Heart Diseases (CHD) and cardiovascular risk factors as per following criteria were included in the study.
-having CHD* (coronary heart diseases) with LDL-C > 130mg/dl**. or -with no CHD and having > 2 risk factors (***) with LDL-C > 160mg/dl**. or -with no CHD and having <1 risk factor (***) with LDL-C > 190mg/dl**. The study protocol and DCF were approved by both Regional Medical Affairs of Sanofi-aventis, Singapore, and Global Medical Affairs of Sanofi-aventis, France. Ethical approval was taken from Bangladesh Medical Research Council (BMRC).
Risk factors
Study Endpoints
The study endpoints were first the number of patients completed the study as per study protocol, number of patients whom fasting LDL and TG were reduced after two month intervention of atorvastatin treatment. There were 1600 patients who had completed the study and their fasting LDL and TG were reduced after 2 months of therapy. No endpoint regarding the efficacy was collected after 2 months of follow up.
Therapeutic intervention:
Atorvastatin (Orva®) manufactured by sanofi-aventis Bangladesh was assigned for the patients for their treatment of hypercholesterolemia.
Atorvastatin was prescribed at a dose of 10 to 80 mg daily with or without their other required therapies at the discretion of investigators and research physicians. The dose was adjusted 2 weekly according to the target lipid levels, the recommended goal of therapy and the patient's response.
The treatment duration was 2 months until the final visit at day 60. Follow up period was 2 months and an interim visits was recommended after one month of treatment. The in-between scheduled visits up to 2 months were arranged according to the requirements.
Results
General overview and basic demography of the patients:
Out of 1685 enrolled patients, finally 1600 (95%) completed the study. 
Inclusion criteria of the patients:
Inclusion criteria were either patient having CHD (angina pectoris/myocardial infarction) + LDL > 130 mg/dl or patient having no CHD + > 2 risk factors + LDL >160 mg/dl or patient having no CHD + < 1 risk factor + LDL > 190 mg/dl and lastly patient's ability and willingness to participate in this trial.
More than half (53.6%) of the patients had CHD with LDL > 130 mg/dl, followed by 38.8% patient without CHD + > 2 risk factors + LDL > 160 mg/dl. No significant association was noted between sex and inclusion criteria (p > 0.05).
More than half of the patients who were 51 years and above had CHD where 85% of the patients who were 61 years and above had CHD. On the other hand, more than half of the patients who were 30-50 years old had no CHD but had 2 or more cardiovascular risk factors. Statistically significant association was noted between age and inclusion criteria (p < 0.05). It is understood that young people having risk factors could prevent CHD in their later age by TLC and clinical management of their risk factors.
Risk factors of the patients:
The details of all the risk factors were elevated total cholesterol, Low HDL cholesterol, Hypertension, Diabetes mellitus, Family history of premature CHD, Cigarette Smoking, Lack of physical exercise, Age > 45 years for men and > 55 years for women are shown in Table-I and Table- 
Basis of the statin recommendation:
From the data of 1600 patients participated in the study cumulatively 3938 reasons came out in four categories on the basis of which atorvastatin was recommended. The participating physicians prescribed atorvastatin mainly for its efficacy and safety which contributed 94.8% and 91.8% cases respectively. Patient's compliance was another reason for selecting atorvastatin in 59% cases.
Doses of the atorvastatin:
Initially mean dose of atorvastatin was 10.81 ± 2.99, while after 2 months it was 11.13 ± 3.34 (2.96 %↑). The mean difference was statistically significant (p < 0.05). Initially mean target dose was 21.08 ± 5.07, while after 2 months it was 21.18 ± 5.15 (0.47 % ↑). The change in mean regarding target dose was not statistically significant (p > 0.05).
Concomitant therapy:
During enrolment OAD/Insulin and antihypertensive medications were mostly reported. Four categories of drugs were more used by the patients at end of the study than their enrolment period. Those were antihypertensive (2.8%↑), anti anginal (1.2%↑), OAD/ Insulin (1.2% ↑) and other medications of various types (4.3%↑). Three drugs were less used than the enrolment period. Those were antithrombotics (2.1 %↓), antiarrhythmics (2.9 %↓), and other lipid lowering agents (0.2 %↓).
General effects of the treatment:
The changes of patient's weight and BMI after 2 months of the treatment are shown in the Table- The initial mean systolic blood pressure (SBP) was 141.04 mm of Hg and after 2 months it was reduced to 133.21 mm of Hg (5.6 %↓). Similarly diastolic blood pressure (DBP) was also reduced from 91.73 mm of Hg to 85.83 mm of Hg (6.4 % ↓) after 2 months. Statistically the change of SBP & DBP was significant (p<0.05). LDL of 23% patients (24.2% male & 20.7% female) was decreased more than 30 mg/dl after 2 months of atorvastatin treatment. Around 59% of the patients reached the treatment goal of reducing LDL > 20 mg/dl as shown in the Table-VI. LDL was decreased more than 30 mg/dl after 2 months of atorvastatin treatment in 31.8% patient age between 30-40 years, 22.9% patient age between 41-50 years, 21.9% of patients age between 51-60 years and 20.8% patient age 61 years and older as shown in the Table- VII. Statistically significant association was noted between changes in LDL and age groups (p < 0.05).
Adverse drug reaction, tolerance and reported effectiveness of atorvastatin:
All doses of atorvastatin were well tolerated. Thirty patients (1.9%) reported at least one treatment-emergent adverse event. The majority of treatment-emergent adverse events were mild and considered unrelated to atorvastatin treatment; the most common being headache, myalgia, nausea, back pain. No discontinuation of study drug due to adverse event was reported. There were no serious adverse events reported. Effectiveness of atorvastatin was reported among 98.1% cases. 98.4% cases stated that prescribed atorvastatin was tolerable. LDL goal (30% of target) was achieved in 98.1 % cases as reported by physicians.
Compliance and assessment of atorvastatin treatment:
In 45.3% cases patients' compliance was reported as very good and in 53.5% was good. In 38.3% cases physician's overall assessment regarding use of atorvastatin was very good and 57% physician' opinion was good. More than 97% cases patient's overall assessment on the treatment was good.
Discussion
The purpose of this open label non comparative study was to evaluate the use of atorvastatin in hypercholesterolemia of cardiovascular risk patients who were inadequately control to diet and exercise. Implication of US NCEP ATP III guidelines among the research clinicians was another intention of the study.
In this study population with mean age 54 years Body mass index (BMI) was lower compared to Western population (24±3 vs 28±4). Hypertensive patients and cigarette smokers were more in this study compare to other study with high risk cardiovascular patients (e.g. The HOPE study) 20 . Recent epidemiologic survey in According to the study design, the diagnosis and the management of adverse events as well as the discontinuation of atorvastatin during follow-up period were authorized to the physicians. Altogether there were 30 individuals who had some forms of adverse event but no discontinuation of study drug was reported. No serious adverse event was reported in this study.
About 98% cases physician reported the drug was effective and in 98.4% cases the drug was tolerable to the participants. Patient's compliance to the atorvastatin treatment was found good in around 98% cases where more than 97% cases patient's overall assessment of the treatment was good. Physician's overall assessment was good in more than 95% cases.
The result of cholesterols lowering effect of atorvastatin and patient's compliance to the treatment in this study is encouraging. Though the follow up period was only two months in this study it shows that hypercholesterolemic patients with risk factors of CHD could get good therapeutic effect from atorvastatin when the clinical management comply with ATP III of the US NCEP guidelines.
Conclusion
One thousand six hundred (1600) patients finally completed the study according to the protocol. Around 59% of the patients reached the treatment goal of reducing LDL > 20 mg/dl. After 2 months of atorvastatin therapy with TLC significant reduction in LDL (26.1% ↓) TG (16.6% ↓) and total cholesterols (21.6% ↓) levels were reported where high-density lipoprotein was increased (16.5% ↓) significantly from the baseline level. The incidence of adverse events was low (2%) and could not be found dose dependent. Overall patients' compliance of the statin therapy was good.
The result demonstrates that study drug atorvastatin is effective, safe and tolerable to Bangladeshi hypercholesterolemic patients with CHD risk factors. To achieve the full therapeutic result of the atorvastatin with good effective treatment compliance the clinical management should comply with the US NCEP ATP III guidelines.
